Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Change in Accured Expenses (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Change in Accured Expenses for 3 consecutive years, with -$370196.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 18409.8% to -$370196.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$216358.0 through Dec 2025, down 701.33% year-over-year, with the annual reading at -$216358.0 for FY2025, 701.33% down from the prior year.
  • Change in Accured Expenses hit -$370196.0 in Q4 2025 for Mangoceuticals, down from -$276656.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $875180.0 in Q1 2024 to a low of -$602885.0 in Q3 2024.
  • Historically, Change in Accured Expenses has averaged -$11355.7 across 3 years, with a median of -$2439.5 in 2023.
  • Biggest five-year swings in Change in Accured Expenses: surged 30498.75% in 2024 and later plummeted 18409.8% in 2025.
  • Year by year, Change in Accured Expenses stood at $51706.0 in 2023, then tumbled by 103.87% to -$2000.0 in 2024, then tumbled by 18409.8% to -$370196.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for MGRX at -$370196.0 in Q4 2025, -$276656.0 in Q3 2025, and $404615.0 in Q2 2025.